Clinical Performance of a Multivariate Index Assay in Detecting Early-Stage Ovarian Cancer in Filipino Women

Velayo, Clarissa; Reforma, K.N.; Sicam, Renee Vina G.; Diwa, Michele H.; Sy, Alvin Duke R.; Tantengco, Ourlad Alzeus G.

doi:10.3390/ijerph19169896

Cited by 3 publications

(4 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fifty-nine percent (13/22) and 32% (7/22) of the cases with malignant transformation were squamous cell carcinoma and mucinous adenocarcinoma, respectively. A very rare malignant transformation reported was carcinoid tumor (1) and follicular carcinoma (1). The most common reason for consult among patients is a palpable abdominal/ pelvic mass (45.5%).…”

Section: Resultsmentioning

confidence: 99%

“…The 5-year prevalence of 25.05 per 100,000 (Globocan 2020) suggests ovarian cancer is a remarkable health burden in the country. 1 Between 2018 and 2019, ovarian cancer remained top 6 of the causes of gynecologic admission in Baguio General Hospital and Medical Center and was the leading cause of death among gynecologic malignancies. Furthermore, ovarian cancer is the 6 th most common malignancy managed in our Cancer Center for the year 2022.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Malignant Transformation in a Mature Cystic Teratoma of the Ovary: A 5-year Descriptive Study

2023

Acta Med Philipp

View full text Add to dashboard Cite

Background and Objective. Malignant transformation (MT) in mature cystic teratoma of the ovary (MCTO) is rare. This descriptive study primarily aims to determine the prevalence rate of MT in MCTO and describe clinicopathologic features, management, and prognosis of patients who developed this rare type of tumor and likewise deliver a review in the light of recent literature.Methods. This is a descriptive observational study of 22 patients with MT in MCTO at a Level 3 Tertiary Public Hospital in Baguio City, Philippines. The clinical and pathological records of each patient were reviewed. Descriptive statistics were used. Results.Between January 2016 to December 2020, of the 369 cases of mature cystic teratoma, 22 cases with malignant transformation were reported with an incidence of 6%. The mean age of diagnosis was 52 years, of which 70% are aged 50 years old and above. Fifty-nine percent (13/22) and 32% (7/22) of the cases were squamous cell carcinoma and mucinous adenocarcinoma, respectively. Very rarely, malignant transformations were carcinoid tumors (1) and follicular carcinoma (1). The most common reason for consult among patients is a palpable abdominal/ pelvic mass (45.5%). Around 60% percent of cases have an elevated CA-125 value with a mean level of 180 U/ml. Seventy-two percent of cases with malignant transformation measured 10 cm or more with the largest mean diameter of 13 cm. Five patients underwent fertility-sparing surgery. Fourteen had staging procedures. Twelve patients were at Stage I. Three were at Stage II. Four and three patients were at Stage III and IV, respectively. Ten patients received adjuvant platinum-based chemotherapy and nine patients warrant no treatment after surgery. The median survival time is 14 months. Conclusion.Although not common, malignant transformation in MCT should be considered in older patients with large tumor sizes and elevated CA-125 assessed as MCT in preoperative and intraoperative assessment. This ovarian malignancy suggests an aggressive behavior but complete resection with systematic staging and indicated adjuvant platinum-based chemotherapy may improve survival.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Malignant Transformation in a Mature Cystic Teratoma of the Ovary: A 5-year Descriptive Study

2023

Acta Med Philipp

View full text Add to dashboard Cite

show abstract

“…However, the diagnostic performance of other ultrasound-based models in combination with biochemical markers available in the Philippines such as CA-125 and MIA2G has not been validated. These biomarkers were shown to have a good diagnostic accuracy for ovarian malignancy [10][11][12][13].…”

Section: Introductionmentioning

confidence: 99%

“…However, there has been no local comprehensive report to evaluate a comparison of all these different ultrasound-based models. Our work evaluating IOTA-LR2 combined with a multivariate index assay (MIA2G) has previously been reported [10,11]. However, the diagnostic performance of other ultrasound-based models in combination with biochemical markers available in the Philippines such as CA-125 and MIA2G has not been validated.…”

Section: Introductionmentioning

confidence: 99%

Diagnostic Performances of Ultrasound-Based Models for Predicting Malignancy in Patients with Adnexal Masses

et al. 2022

Self Cite

View full text Add to dashboard Cite

This study compared the diagnostic performance of different ultrasound-based models in discriminating between benign and malignant ovarian masses in a Filipino population. This was a prospective cohort study in women with findings of an ovarian mass on ultrasound. All included patients underwent a physical examination before level III specialist ultrasonographic and Doppler evaluation using the different International Ovarian Tumor Analysis (IOTA) Group’s risk models. Serum CA-125 and a second-generation multivariate index assay (MIA2G) were also determined for all patients. The ovarian imaging and biomarker results were correlated with the histological findings. A total of 260 patients with completed ultrasound, CA-125, MIA2G, and histopathologic results was included in the study. The presence of papillae with blood flow and irregular cyst walls during the ultrasound were significantly associated with a 20-fold (OR: 20.13, CI: 8.69–46.67, p < 0.01) and 10-fold (OR: 10.11, CI: 5.30–19.28, p < 0.01) increase in the likelihood of a malignant lesion, respectively. All individual sonologic procedures performed well in discerning malignant and benign ovarian lesions. IOTA-LR1 showed the highest accuracy (82.6%, 95% CI: 77.5–87%) for identifying ovarian cancer. IOTA-ADNEX showed the highest sensitivity (93.3%, 95% CI: 87.2–97.1%) while IOTA-LR2 exhibited the highest specificity (84.4%, 95% CI: 77.3–90%). Among the different serial test combinations, IOTA-LR1 with MIA2G and IOTA-LR2 with MIA2G showed the highest diagnostic accuracy (AUROC = 0.82). This study showed that all individual ultrasound-based models performed well in discerning malignant and benign ovarian lesions, with IOTA-LR1 exhibiting the highest accuracy.

show abstract

Novel inflammatory markers and prognostic importance of platinum-sensitive ovarian carcinoma relapse

2023

View full text Add to dashboard Cite

Introduction/Objective. Ovarian carcinomas are the deadliest gynecological tumors. Despite advances in treatment options, survival rates are still not at the desired level. Since clinical signs are not typical in early-stage disease, 2/3rd of patients are diagnosed late. Carbohydrate Antigen 125 (CA125) does not have sufficient sensitivity and specificity in early-stage disease and early post-relapse progression. There is a need for a simple and cost-effective marker that correlates with CA125. For this purpose, we aimed to evaluate the potential of systemic inflammatory markers? as diagnostic aids. Methods. Patients with platinum-sensitive recurrent ovarian carcinomas were preferred because the treatment options were more diverse than the resistant group. Using retrospective data collection, 105 patients with platinum-sensitive recurrent ovarian carcinoma, admitted in the last four years were included in the study. Complete blood count data was recorded based on recurrence and progression periods. Results. When the systemic immune inflammatory index (SII) values were evaluated in combination with CA125 in terms of progression during the control visits after platinum-sensitive disease recurrence treatment, progression detection proportions increased to 97.5%, which was 82.9% when only CA125 was used. On the other hand, false positivity, which was 18.5% for CA125 alone, decreased to 2.5% when combined with SII. Furthermore, neutrophil lymphocyte ratio, WBC, and neutrophil values showed correlations with high CA125 values. Conclusion. The SII value could be used together with CA125 because it is easy to use, accessible, and has low cost in clinical practice, as well as to increase the accuracy rate and make precise corrections in the false positivity rate.

show abstract

Clinical Performance of a Multivariate Index Assay in Detecting Early-Stage Ovarian Cancer in Filipino Women

Cited by 3 publications

References 37 publications

Malignant Transformation in a Mature Cystic Teratoma of the Ovary: A 5-year Descriptive Study

Malignant Transformation in a Mature Cystic Teratoma of the Ovary: A 5-year Descriptive Study

Diagnostic Performances of Ultrasound-Based Models for Predicting Malignancy in Patients with Adnexal Masses

Novel inflammatory markers and prognostic importance of platinum-sensitive ovarian carcinoma relapse

Contact Info

Product

Resources

About